RahulDoc

We have 35 doctors in Lok Sabha. Did any body raises there voice for dausa incidence. @IMAIndiaOrg @drrmittal

Our wonderful bone marrow transplant team @fortis_hospital @rajshekharucms @mehak_trehan @RahulDoc2 @docsherook @shanuaswam @DrNeha90356702 @drshrinidhi2020 @BhartiSh85 @vishwa_mak @DevyaniSurange

Hematologists treat acute leukemias at most centers across the country . Excluding hematologists from clinical trials of “HEMATOLOGICAL MALIGNANCIES “ makes absolutely no sense and is an irony in itself . Really unfortunate that instead of widening access to patients , policy decisions ignore ground realities and come up with such absurd ideas @jayastuMD @royjpalatty @VergheseRenjith @chepsyphilip @TK2K6 @ishbtish @hematologydr @TribikramHemat @TikareNakul @Rohanhematdoc @shanuaswam @RahulDoc2 @dranupjdevasia

@prantar @CDSCO_INDIA_INF @MoHFW_INDIA @NITIAyog @CDSCO_INDIA_INF should immediately look into this

Has the @CDSCO_INDIA_INF conveniently forgotten that there are #hematologists who are specially trained to treat #bloodcancers ? This order has surprised me as I was a member of the Subject Expert Committee of CDSCO on #HematologyOncology for more than 5 years. If CDSCO feels hematooncologists are not competent to conduct #clinicaltrials on patients with blood cancers then should we stop treating these patients ? @NMC_IND @MoHFW_INDIA @DrPMPGI @RahulDoc2 @drtulikahemat

@RahulBanerjeeMD @Mohty_EBMT Very true

#COMy2026 #evangelosterpos summarizing one of most practice-changing (even if niche) data I’ve seen for bone-modifying agents in myeloma. For moderate CKD, consider denosumab 60 mg not 120 mg to lower hypoCa. Not randomized, but very reasonable given how severe hypoCa can be!

Officially Convocated today in DM Clinical Hematology, AIIMS New Delhi. 🎓 Deeply grateful to the institute that shaped the way I think, learn, question, and practice hematology. The journey has been intense, humbling, and immensely enriching. Thankful to all those who have been part of this incredible journey. The beginning of a greater responsibility ahead! Onwards, with a full heart <3

1/ Is EPO contraindicated in multiple myeloma? No. But ESA use in myeloma is not “routine anemia correction.” It is a supportive-care intervention after asking 3 questions: 1. Is the myeloma controlled? 2. Is anemia from CKD/chemo/inflammation rather than progression? 3. Is the thrombotic risk acceptable? In myeloma, Hb is a disease marker before it is a prescription trigger. @RahulDoc2 @IndMyAcGp

4/ The field has already answered part of this question. When daratumumab moved with a PI into frontline transplant-ineligible myeloma, it did not move as D-Vd. It moved as: • D-VMP in ALCYONE • D-VRd in CEPHEUS • Anti-CD38 + VRd strategy in IMROZ/CEPHEUS era So the real question is not: “Can we give D-Vd upfront?” It is: If D-Vd is relapse-proven but not frontline-tested, should we move it upfront in selected patients OR is first line too precious for extrapolated evidence? #MMSM #MultipleMyeloma #Myeloma #Hematology #MedEd @RahulDoc2 @nikhil91sjmc @IndMyAcGp

FDG PET and CXCR4 PET may image the same patient, but they answer different biological questions. Same patient, sequential imaging: 1. Baseline: FDG-avid myeloma 2. After treatment: FDG PET/CT negative 3. Same timepoint: CXCR4 PET still positive 4. Later: CXCR4 PET clears This is the kind of discordance that makes myeloma imaging fascinating. FDG PET asks: Is the disease glycolytically active? CXCR4 PET asks: Is receptor-expressing disease biology still present? In myeloma, both questions matter. CXCR4 imaging may reveal residual biologic heterogeneity and potential targetable disease even when FDG appears silent. The clinical meaning still needs correlation with MRD, paraprotein/light chains, marrow, and outcomes :but the visual lesson is powerful. When FDG PET becomes negative but CXCR4 PET remains avid, are we looking at residual myeloma biology that conventional metabolic imaging is no longer capturing? @VincentRK @DrOlaLandgren @ProfKHerrmann @SNM_MI @JournalofNucMed @szusmani

4/ So maybe the right question is not: “Can we reuse teclistamab vials?” Maybe it is: “Can controlled vial optimization be formally studied- with aseptic compounding, sterility checks, defined time limits, infection-control oversight and outcome tracking?” Quiet practice is weak evidence. Structured data is science.

Answer sought, rare only 60 cases so far If anyone knows any support groups with these cases pls dm, we want to help the family #RareDisease @CheckOrphan @RareDiseases @rarediseaseday @mboat7 #mboat7 @RahulDoc2 @nikhil91sjmc @OrphanDiseasePP @TeresaScruton @OrphanDiseasePP @ODActivists

@drshrinidhi2020 @CheckOrphan @RareDiseases @rarediseaseday @nikhil91sjmc @OrphanDiseasePP @TeresaScruton Wonderful

1/ In myeloma spine disease, radiotherapy treats biology, kyphoplasty treats biomechanics. Confusing the two is how we undertreat pain- or undertreat risk. IMWG separates them accordingly: • Balloon kyphoplasty: grade A • Vertebroplasty: grade C for painful vertebral compression fractures • Radiotherapy: grade C for uncontrolled pain, impeding/symptomatic spinal cord compression or pathological fractures. @RahulBanerjeeMD @SahgalArjun @JoshuaAHirsch @TracyABalboni @IMFmyeloma @VincentRK

@mehak_trehan @RahulBanerjeeMD @VincentRK Wonderful

1/ Encouraging early experience with Belantamab Mafodotin in a 60/M with R/R MM. In a patient with limited remaining options, even an early biochemical signal of response can be clinically meaningful and may help inform confidence in subsequent dosing @RahulBanerjeeMD @VincentRK @ManniMD1 @Myeloma_Doc @nikhil91sjmc @RahulDoc2 @MirghSumeet

@MahavirSinghvii Well deserved proud of u

Mahaveer Singhvi is India’s new consul general in Toronto hindustantimes.com/s/1QQAPcO

Talquetamab bridging: Turning uncontrolled EMD into CAR-T before BCMA CART.

@docsherook Great case. Great synergy @fortis_hospital for precision hematology

@sumersethi In India itself our 5 yr median survival is 89 percent

There was a time when a diagnosis like multiple myeloma felt like a countdown. Today, it feels like a conversation about years, milestones, and life still unfolding. Science didn’t just add drugs it added time. Time to see children grow. Time to celebrate anniversaries. Time to hope again. This is the power of modern oncology not just prolonging survival, but restoring possibility. Not just treating disease, but giving life back to patients and families. Every clinical trial, every molecule, every researcher turning cancer from a sentence into a journey. Science is not just advancing. It is giving time. And time is everything. #MultipleMyeloma #CancerCare #PowerOfScience

Indian regulators have done the right thing @NMC_IND